Medical/Pharmaceuticals
Daewoong Pharmaceutical Unveils 'Innovative Drug Delivery Technologies' in Milan--From World's First Microneedle Therapy to Once-a-Month Obesity Treatment
MILAN, Oct. 10, 2024 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Chang-jae Lee) announced on the 9th that they will present their cutting-edge drug delivery technologies, including the world's first microneedle-based drugs, at 'CPHI Worldwide 2024'—the world's largest phar...
2024-10-10 06:16
3026
Centivax Selects Global CDMO BioCina to Initiate cGMP Manufacturing of Revolutionary Universal Influenza Vaccine
ADELAIDE, South Australia, Oct. 9, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced a new partnership with Centivax, Inc., for a project involving cell line development, cell banking and plasmid DNA manufact...
2024-10-09 23:37
3314
Arbele Announces Strategic Collaborations on AI Precision Oncology and Manufacturing to Advance CDH17-Targeted Immunotherapeutics
SEATTLE, Oct. 9, 2024 /PRNewswire/ -- Arbele, a leading innovator in biopharmaceutical & biotechnology focused on targeting cadherin-17 (CDH17), is pleased to announce strategic collaborations in precision oncology using artificial intelligence (AI) to advance targeted immunotherapeutics of bisp...
2024-10-09 23:00
1998
Inaugural Health and Wellbeing Forum Discussed about Co-creating Healthier Hong Kong for all
This event brought together over 60 representatives from patient organizations, academia, and healthcare community to explore the possibilities of achieving maximum health equity inHong Kong HONG KONG, Oct. 9, 2024 /PRNewswire/ -- Pfizer Hong Kong held its inaugural "Health & Well-being Forum" t...
2024-10-09 22:17
2997
ZEISS expands ophthalmic offerings to improve patient care with new digital AI tools and revolutionary surgical solutions
Showcasing at AAO 2024: * ZEISS VisioGen offers a cutting-edge, AI-driven solution designed to enhance refractive patient communication and streamline clinic operations. * ZEISS Milestone: Celebrating more than 10 million eyes treated with lenticule extraction solutions utilizing ZEISS SMIL...
2024-10-09 21:00
2896
Baird Medical Lists in the U.S. on the Nasdaq Exchange
Company Rings Opening Bell to Celebrate Closure of Business Combination and Begins Journey as a Public Company; Shares trade under "BDMD" Ticker FORT MILL, S.C., Oct. 9, 2024 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leading micro...
2024-10-09 20:30
2181
ShiraTronics Raises $66 Million in Oversubscribed Series B Financing to Advance Pioneering Treatment for Chronic Migraine
Implantable Neuromodulation System Shows Early Promise in Improving Patient Quality of Life by Reducing Monthly Headache Days and Severity of Migraine Attacks MINNEAPOLIS, Oct. 9, 2024 /PRNewswire/ -- ShiraTronics, a clinical-stage medical device company developing neurostimulation therapies fo...
2024-10-09 20:12
1871
International Collaboration Addresses Rising Cancer Rates in South America
National Comprehensive Cancer Network and Latin American Cooperative Oncology Group to publish cancer treatment guidelines tailored forBrazil. PLYMOUTH MEETING, Pa., Oct. 9, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers in the Unite...
2024-10-09 20:07
1640
Nona Biosciences Enters Strategic Collaboration with OverT Bio to Advance Next-Generation Cell Therapies for Solid Tumors
CAMBRIDGE, Mass., Oct. 9, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), today announced a strategic collaboration with OverT Bio, aNew York-based biotechnology company. The collaboration will focus on developing ne...
2024-10-09 20:00
1936
New INTREPID Alliance Antiviral Landscape Report Highlights Urgent Need to Bolster R&D Pipeline in Support of Global Pandemic Preparedness Efforts
Current mpox outbreak underscores gaps in access to medical countermeasures to help mitigate the severity of future outbreaks CAMBRIDGE, Mass., Oct. 9, 2024 /PRNewswire/ -- Today, the INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating antiviral tr...
2024-10-09 19:00
1652
Alpha Fusion Accelerates Astatine-based Drug Discovery with Series B Funding
OSAKA, Japan, Oct. 9, 2024 /PRNewswire/ -- Alpha Fusion, Inc. (CEO: Sunao Fujioka, headquartered in Kita-ku, Osaka), has raised a total of ¥1.02 billion through a Series B funding round. The round was led by SBI Investment Co., Ltd. andOSAKA University Venture Capital, with participation from sev...
2024-10-09 15:23
1994
The CDE has Granted Breakthrough Therapy Designation to LBL-024, a Bispecific Antibody that Targets PD-L1 and 4-1BB, Developed by Leads Biolabs, for the Treatment of Extrapulmonary Neuroendocrine Carcinoma.
NANJING, China, Oct. 9, 2024 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs") announced that Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation to LBL-024, an anti-PD-L1/4-1BB bispecific antibody indepe...
2024-10-09 13:38
2383
Joint Venture Company Established for Incubation of Early Drug Discovery Programs; Investment from Takeda, Astellas and Sumitomo Mitsui Banking
TOKYO, Oct. 8, 2024 /PRNewswire/ -- Ciconia Bioventures Inc. (Representative Director, Founder CEO:Toshio Fujimoto, "Ciconia") today announced its establishment as a joint venture company based on a master agreement signed on April 22, 2024 by Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:...
2024-10-09 10:00
1970
AWAK Transforms into Vivance, Unveiling a New Brand Identity
SINGAPORE, Oct. 9, 2024 /PRNewswire/ -- AWAK Technologies, a pioneer in innovative kidney care is excited to announce its rebranding toVivance. The name, derived from 'viva' and 'advance', embodies vitality and progress - hallmarks of the company's commitment to revolutionizing kidney health. AW...
2024-10-09 08:00
3035
Rege Nephro Co., Ltd. Successfully Completes Series B Funding to Accelerate Kidney Disease Therapy Trials
KYOTO, Japan, Oct. 7, 2024 /PRNewswire/ -- Rege Nephro Co., Ltd. (
https://www.regenephro.co.jp/
2024-10-09 07:39
3681
Baird Medical to Participate in Roth's 3rd Annual Healthcare Opportunities Conference
GUANGZHOU, China, Oct. 8, 2024 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China which has recently expanded into the U.S. market following its receipt of US...
2024-10-09 04:30
2035
Seegene and Werfen Finalize Partnership Agreement on Technology-Sharing Initiative
* Werfen, a worldwide leader in specialized diagnostics, becomes the first European company to finalize the partnership agreement to join Seegene's technology-sharing initiative * The two companies will co-establish a NewCo in Spain to serve as a strategic hub inEurope, accelerating global ex...
2024-10-08 21:00
2801
LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance
GAITHERSBURG, Md., Oct. 8, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for in...
2024-10-08 20:30
3930
Korea's SK bioscience Acquires Stake in U.S. Biotech Fina Biosolutions
* SK bioscience invested USD 3 million in FinaBio, a U.S. company specializing in next-generation conjugate vaccine technology. * With the agreement, SK bioscience expects to improve the immunogenicity and productivity of conjugate vaccines, including those for pneumoniae and typhoid. * The ...
2024-10-08 20:00
2449
Pierre Fabre Laboratories and Scorpion Therapeutics Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-241/STX-241, a Mutant-Selective Inhibitor Intended To Treat Locally Advanced or Metastatic Non-Small Cell Lung Cancer
PFL-241/STX-241 is a highly selective, and potentially best-in-class fourth generation epidermal growth factor receptor ("EGFR") inhibitor One of two EGFR programs being developed with Scorpion Therapeutics CASTRES, France and BOSTON, Oct. 8, 2024 /PRNewswire/ -- Pierre Fabre Laboratories, a glo...
2024-10-08 20:00
2187
Week's Top Stories
Most Reposted
Agoda Launches Agoda Impact Lab at ASEAN Tourism Forum
[Picked up by 322 media titles]
2026-01-29 15:06
Wonder Raises USD 12 Million Venture Debt from HSBC Innovation Banking to Drive Growth and Expansion
[Picked up by 322 media titles]
2026-02-02 10:00
AI adoption is widespread, but developer confidence is still catching up, Agoda report finds
[Picked up by 312 media titles]
2026-02-03 11:00
Mastercard Launches Portfolio of Fleet Solutions in Asia Pacific
[Picked up by 304 media titles]
2026-02-04 09:00Colebrook Bosson Saunders Officially Launches Lana, A Circular Ergonomic Laptop Stand for the Hybrid Generation
[Picked up by 303 media titles]
2026-02-03 12:00